Tocilizumab Effectiveness After Switching from Intravenous to Subcutaneous Route in Patients with Rheumatoid Arthritis: The RoSwitch Study

Autor: Jean Darloy, Nicolas Segaud, Jean-Hugues Salmon, Jean-Paul Eschard, Vincent Goëb, Xavier Deprez, Marie-Hélène Guyot, Eric Houvenagel, Nicolas Lecuyer, Laurent Marguerie, Samuel Gally, David Pau, Isabelle Idier, Guy Baudens, René-Marc Flipo

Publikováno v: Rheumatology and Therapy, Vol 6, Iss 1, Pp 61-75 (2019)

Abstract Introduction The main objective of this work was to assess the maintenance of effectiveness of subcutaneous tocilizumab 6 months after switching from intravenous to subcutaneous formulation in patients with rheumatoid arthritis (RA) in a rea

Externí odkaz: https://doaj.org/article/a5e746db2ad043b8942c356d749ad9e1

Characteristics of Patients Treated with JAK Inhibitors in Rheumatoid Arthritis before versus after VTE Risk Warnings

Autor: Cécile Philippoteaux, Valentine Deprez, Aurore Nottez, Emeline Cailliau, Eric Houvenagel, Xavier Deprez, Peggy Philippe, Tristan Pascart, René-Marc Flipo, Vincent Goëb, Jean-Guillaume Letarouilly

Publikováno v: Journal of Clinical Medicine; Volume 12; Issue 1; Pages: 207
Journal of Clinical Medicine
Journal of Clinical Medicine, 2023, 12 (1), pp.207. ⟨10.3390/jcm12010207⟩

Background: Baricitinib (BARI) or Tofacitinib (TOFA) were the first Janus Kinase Inhibitors (JAKi) to be marketed in rheumatoid arthritis (RA). Concerns regarding venous thromboembolism (VTE) risk have emerged during the past years. The aim of the st

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::345f568c8cd4d55af4295861fb9aaa49

First case of Kingella kingae spondylodiscitis in an elderly man with a molecular characterization of the responsible strain

Autor: Franck Grados, Jean-Philippe Lanoix, François Peltier, Vincent Goëb, Morgane Choquet, Marie Doussiere

Publikováno v: Infectious Diseases Now. 51:497-499

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_________::8f67f49cfc7b0f07611bb9b4b3419828
https://doi.org/10.1016/j.idnow.2020.10.003

Comparison of Rheumatoid Arthritis Patients’ 2-Year Infliximab, Abatacept, and Tocilizumab Persistence Rates

Autor: Laetitia Diep, Vincent Barbier, Marie Doussière, Estelle Touboul, Claire Jesson, Valentine Deprez, Jean-Marc Sobhy-Danial, Patrice Fardellone, Vincent Goëb

Publikováno v: Journal of Clinical Medicine; Volume 11; Issue 20; Pages: 5978

Background: Drug persistence reflects an agent’s efficacy and safety in routine practice. This study was undertaken to compare the 2-year persistence rates of three biologic disease-modifying antirheumatic drugs (bDMARDs) used to treat rheumatoid a

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::d4bc8d93bcdbf7ffa876e34da30dbd20
https://doi.org/10.3390/jcm11205978

Premedication as primary prophylaxis does not influence the risk of acute infliximab infusion reactions in immune-mediated inflammatory diseases: A systematic review and meta-analysis

Autor: Jean Philippe Le Mouel, Marion Tilmant, Momar Diouf, Julien Loreau, Mathurin Fumery, Clara Yzet, Vincent Goëb, Siddarth Singh, Eric Nguyen-Khac, Jean-Louis Dupas, Justine Turpin, Franck Brazier

Publikováno v: Digestive and Liver Disease
Digestive and Liver Disease, WB Saunders, 2019, 51, pp.484-488. ⟨10.1016/j.dld.2018.12.002⟩

Introduction Up to 25% of patients treated with infliximab experience hypersensitivity reactions. Prophylactic premedication prior to infliximab infusion, comprising corticosteroids and/or antihistamines, is widely used in clinical practice but its e

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::d43a0d446d79d15941cbe61720921b8c
https://doi.org/10.1016/j.dld.2018.12.002